Anti-Aging & Longevity 2 min read

Epithalon

META-TITLE: [TODO: Epithalon — Telomerase Activator Research Profile | Brand]
META-DESC: [TODO: Epithalon (Epitalon) research profile — tetrapeptide telomerase activator, pineal gland, Khavinson longevity studies.]

[TODO] Hook — Epithalon as the only known peptide to directly activate telomerase, developed from decades of Russian longevity research by Prof. Khavinson

[IMAGE: Epithalon molecular structure — Ala-Glu-Asp-Gly tetrapeptide]

What is Epithalon?

[TODO] Full name — Epithalon (Epitalon), Ala-Glu-Asp-Gly tetrapeptide
[TODO] Origin — synthetic analog of Epithalamin, extracted from pineal gland
[TODO] Developer — Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology
[TODO] Primary action — telomerase activation in somatic cells
[TODO] Research history — 35+ years of Russian studies, limited Western replication

Mechanism of Action

[IMAGE: Telomere shortening diagram — showing how Epithalon activates telomerase to maintain telomere length]

[TODO] Telomerase activation — induces hTERT expression, elongates telomeres
[TODO] Pineal gland — stimulates melatonin production, restores circadian rhythm
[TODO] Antioxidant — lipid peroxidation reduction, ROS scavenging
[TODO] Gene regulation — normalizes T-lymphocyte function, immune modulation

Research Highlights

[TODO] Telomere elongation — 33% increase in telomerase activity in human cell cultures
[TODO] Lifespan — 13.3% increase in lifespan in animal models (Khavinson)
[TODO] Melatonin — restored melatonin secretion in elderly subjects (Russian studies)
[TODO] Cancer — some antitumor properties observed, not pro-tumorigenic
[TODO] Retinal — protective effects in retinitis pigmentosa models

Dosing Protocols (Research Context)

[TODO] Standard protocol — 5-10mg/day for 10-20 days, SC or IV
[TODO] Cycling — 10 day on, 6 months off (Khavinson protocol)
[TODO] Long-term — 2-3 cycles per year
[TODO] Storage — standard peptide reconstitution, stable

Safety & Considerations

[TODO] Excellent safety — no adverse effects reported in Khavinson studies
[TODO] Telomerase concern — theoretical cancer risk, but studies show no tumor promotion
[TODO] Data limitation — most research from single Russian institution, replication needed
[TODO] No Western clinical trials — regulatory status varies by jurisdiction